Navigation Links
NeoStem Secures $250,000 in an Above Market Financing and Expands Its Relationship With New England Cryogenic Center, Inc.

NeoStem Opens New Boston Area Facility

NEW YORK, Oct. 27 /PRNewswire-FirstCall/ -- NeoStem, Inc. (AMEX: NBS - News), NeoStem, Inc., which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need, announced today that it has closed on a private placement financing in the amount of $250,000. The funds will assist the Company in launching its adult stem cell collection network in the New York City market and increasing its research and development activities prior to receipt of the $800,000 in federal funds that have been earmarked by the Department of Defense through the FY09 Appropriations Bill to evaluate the efficacy and potential use of stem cell therapy for treating injuries suffered by U.S. military and first responders.

The private placement financing consists of units priced at $1.25 per unit with each unit consisting of one share of common stock and a warrant to purchase one share of common at $1.75. Dr. Robin Smith, Chairman and CEO of NeoStem commented, "We have felt that our stock price has been undervalued in light of recent stock market conditions and current credit crunch and this $250,000 private investment at above market prices helps to validate our sentiments. We believe we are in an exciting new phase of our development and we take comfort in the fact that this private placement, along with the $800,000 earmark from the US Department of Defense, show confidence in our technology and the importance that adult stem cell therapy may one day represent in medical treatment."

Dr. Smith also took this opportunity to comment on NeoStem's recently expanded relationship with New England Cryogenic Center, Inc. "NECC has been a leader in cryogenics for over 25 years and we have carefully chosen their state of the art facility in which to establish our own stem cell basic research and development capacity to seek to accelerate the development of our very small embryonic like (VSEL) stem cell technology." VSELs have been identified in adult bone marrow and resemble embryonic stem cells both morphologically and transcriptionally. NeoStem's new Boston area facility will focus on quantifying VSEL mobilization and establishing laboratory conditions for their expansion. These research efforts will be aimed at directing VSEL differentiation into various progenitor populations with the goal of developing adult stem cell therapies.

"NeoStem continues to achieve important strategic milestones during this very exciting period of its expansion and growth. We are proud to have them as a partner," said John Rizza, CEO of New England Cryogenic Center, Inc.

The securities sold in the private placement were sold without registration under the Securities Act of 1933, as amended (the "Act") and may not be resold unless subsequently registered under the Act or pursuant to an exemption from registration under the Act.

About NeoStem, Inc.

NeoStem is developing a network of adult stem cell collection centers that are focused on enabling people to donate and store their own (autologous) stem cells when they are young and healthy for their personal use in times for future medical need. The Company has also recently entered into research and development through the acquisition of a worldwide exclusive license to technology to identify and isolate VSELs (very small embryonic-like stem cells), which have been shown to have several physical characteristics that are generally found in embryonic stem cells.

For more information, please visit:

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results, including any successful development of its adult stem cell collection network and any successful development of its VSEL technology into therapies, could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's periodic filings with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.


NeoStem, Inc.

Robin Smith, Chief Executive Officer

T: 212-584-4180


SOURCE NeoStem, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Suzanne Somers, Renowned Author, Medical Advocate, and Official Spokesperson for NeoStem, Inc., Inspires the Audience on The Ellen Degeneres Show
2. NeoStem Forges Ahead in Its Plan to Open Adult Stem Cell Collection Centers in Key Locations that Can Serve as Hubs to Service Clients Nationwide
3. NeoStem Expands Adult Stem Cell Collection Network, Gains Footprint in Key Los Angeles Market and Initiates Waitlist
4. Suzanne Somers To Promote Growing Importance of Storing Your Own Adult Stem Cells Under Alliance With NeoStem, Inc.
5. NeoStem Announces Private Placement Financing to Advance Marketing Campaign; Financing Includes Investment from New England Cryogenic Center
6. NeoStem to Expand Stem Cell Collection Center Network to Florida
7. NeoStem Featured in WCBS-TV Health Watch Segment on Adult Stem Cells
8. NeoStems Denis Rodgerson, Ph.D. to Lecture on Stem Cells and Regenerative Medicine at University of Nevada Las Vegas Campus
9. NeoStem to Present at Third Annual Stem Cell Summit in New York City
10. NeoStem Announces NY State License for Adult Stem Cell Collection
11. Transave, Inc. Secures $12.5 Million in New Financing
Post Your Comments:
(Date:11/25/2015)... --> ... 2020 report analyzes that automating biobanking workflow will ... long-term samples, minimizing manual errors, improving the workflow ... errors such as mislabeling or inaccurate sample barcoding ... a vital role in blood fractionation, DNA extraction, ...
(Date:11/25/2015)... , November 25, 2015 Studies ... and human plaque and pave the way for more effective ... in cats     --> ... commonly diagnosed health problems in cats, yet relatively little was ... Two collaborative studies have been conducted by researchers from the ...
(Date:11/25/2015)... 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; ... and prospects remain fundamentally strong and highlights the ... recently received DSMB recommendation to continue the ZoptEC ... of the final interim efficacy and safety data ... in men with heavily pretreated castration- and Taxane-resistant ...
(Date:11/25/2015)... The Global Genomics Industry ... and in-depth study on the current state of ... ) , The report provides ... classifications, applications and industry chain structure. The Genomics ... including development trends, competitive landscape analysis, and key ...
Breaking Biology Technology:
(Date:11/10/2015)... , Nov. 10, 2015  In ... on the basis of product, type, application, ... included in this report are consumables, services, ... report are safety biomarkers, efficacy biomarkers, and ... this report are diagnostics development, drug discovery ...
(Date:11/9/2015)... , Nov. 9, 2015  Synaptics Inc. (NASDAQ: ... today announced broader entry into the automotive market with ... match the pace of consumer electronics human interface innovation. ... are ideal for the automotive industry and will be ... Europe , Japan ...
(Date:10/29/2015)... MINNETONKA, Minn. , Oct. 29, 2015   ... that supports the entire spectrum of clinical research, is ... the Minnesota High Tech Association (MHTA) as one of ... in the "Software – Small and Growing" category. The ... and individuals who have shown superior technology innovation and ...
Breaking Biology News(10 mins):